Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

PHASE2CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Breast CancerMetastases
Interventions
DRUG

Ixabepilone

Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.

Trial Locations (45)

Unknown

Local Institution, La Verne

Local Institution, Meriden

Local Institution, Jacksonville

Local Institution, Baltimore

Local Institution, Boston

Local Institution, New York

Local Institution, Asheville

Local Institution, Charlotte

Local Institution, Pittsburgh

Local Institution, Providence

Local Institution, Chattanooga

Local Institution, Jackson

Local Institution, Knoxville

Local Institution, Nashville

Local Institution, Houston

Local Institution, San Antonio

Local Institution, Salt Lake City

Local Institution, Buenos Aires

Local Institution, Santa Fe

Local Institution, Montreal

Local Institution, Besançon

Local Institution, Bobigny

Local Institution, Clermont-Ferrand

Local Institution, Dijon

Local Institution, Lyon

Local Institution, Marseille

Local Institution, Vandœuvre-lès-Nancy

Local Institution, Frankfurt

Local Institution, Frankfurt Hoechst

Local Institution, Mérida

Local Institution, Chihuahua City

Local Institution, Distrito Federal

Local Institution, Amsterdam

Local Institution, Leiden

Local Institution, Oslo

Local Institution, Trondheim

Local Institution, Port Elizabeth

Local Institution, Fichardtpark

Local Institution, Pretoria

Local Institution, Overport

Local Institution, Panorama

Local Institution, Helsingborg

Local Institution, Lund

Local Institution, Malmo

Local Institution, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

R-Pharm

INDUSTRY